Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 129

1.

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.

Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B.

Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Review.

PMID:
28721928
2.

Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework.

Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, Varrone A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:228-242. doi: 10.1016/j.neurobiolaging.2016.04.026. Review.

PMID:
28317651
3.

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, Garibotto V, Herholz K, Nobili F, Nordberg A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:214-227. doi: 10.1016/j.neurobiolaging.2016.07.012. Review.

PMID:
28317650
4.

Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, Nobili F, Ratib O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:183-195. doi: 10.1016/j.neurobiolaging.2016.03.033. Review.

PMID:
28317648
5.

Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18F-MNI-659 and 11C-raclopride with correction for partial volume effect.

Fazio P, Schain M, Mrzljak L, Amini N, Nag S, Al-Tawil N, Fitzer-Attas CJ, Bronzova J, Landwehrmeyer B, Sampaio C, Halldin C, Varrone A.

Neuroimage. 2017 May 15;152:330-339. doi: 10.1016/j.neuroimage.2017.02.047. Epub 2017 Feb 28.

PMID:
28254508
6.

The immune response of the human brain to abdominal surgery.

Forsberg A, Cervenka S, Jonsson Fagerlund M, Rasmussen LS, Zetterberg H, Erlandsson Harris H, Stridh P, Christensson E, Granström A, Schening A, Dymmel K, Knave N, Terrando N, Maze M, Borg J, Varrone A, Halldin C, Blennow K, Farde L, Eriksson LI.

Ann Neurol. 2017 Apr;81(4):572-582. doi: 10.1002/ana.24909. Epub 2017 Apr 11.

PMID:
28253549
7.

[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods.

Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S, Bagnara MC, Borght TV, Jonsson C, de Nijs R, Hesse S, Koulibaly PM, Akdemir UO, Koole M, Tatsch K, Varrone A.

EJNMMI Phys. 2017 Dec;4(1):8. doi: 10.1186/s40658-017-0175-6. Epub 2017 Jan 28.

8.

In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects.

Delnomdedieu M, Forsberg A, Ogden A, Fazio P, Yu CR, Stenkrona P, Duvvuri S, David W, Al-Tawil N, Vitolo OV, Amini N, Nag S, Halldin C, Varrone A.

Neuropharmacology. 2017 May 1;117:171-181. doi: 10.1016/j.neuropharm.2017.01.016. Epub 2017 Jan 22.

PMID:
28122201
9.

The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging.

Dickson JC, Tossici-Bolt L, Sera T, Booij J, Ziebell M, Morbelli S, Assenbaum-Nan S, Borght TV, Pagani M, Kapucu OL, Hesse S, Van Laere K, Darcourt J, Varrone A, Tatsch K.

EJNMMI Res. 2017 Dec;7(1):10. doi: 10.1186/s13550-016-0253-0. Epub 2017 Jan 24.

10.

Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.

Beaumont V, Zhong S, Lin H, Xu W, Bradaia A, Steidl E, Gleyzes M, Wadel K, Buisson B, Padovan-Neto FE, Chakroborty S, Ward KM, Harms JF, Beltran J, Kwan M, Ghavami A, Häggkvist J, Tóth M, Halldin C, Varrone A, Schaab C, Dybowski JN, Elschenbroich S, Lehtimäki K, Heikkinen T, Park L, Rosinski J, Mrzljak L, Lavery D, West AR, Schmidt CJ, Zaleska MM, Munoz-Sanjuan I.

Neuron. 2016 Dec 21;92(6):1220-1237. doi: 10.1016/j.neuron.2016.10.064. Epub 2016 Dec 1.

PMID:
27916455
11.

Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex.

Häggkvist J, Tóth M, Tari L, Varnäs K, Svedberg M, Forsberg A, Nag S, Dominguez C, Munoz-Sanjuan I, Bard J, Wityak J, Varrone A, Halldin C, Mrzljak L.

J Nucl Med. 2017 Apr;58(4):617-622. doi: 10.2967/jnumed.116.180497. Epub 2016 Nov 10.

PMID:
27856625
12.

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, Comley RA, Fazio P, Jamois C, Nakao R, Ejduk Z, Al-Tawil N, Akenine U, Halldin C, Andreasen N, Ricci B.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):382-391. doi: 10.1007/s00259-016-3510-6. Epub 2016 Sep 16.

13.

Guidelines to PET measurements of the target occupancy in the brain for drug development.

Takano A, Varrone A, Gulyás B, Salvadori P, Gee A, Windhorst A, Vercouillie J, Bormans G, Lammertsma AA, Halldin C.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2255-2262. Epub 2016 Aug 11.

14.

Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder.

Tiger M, Farde L, Rück C, Varrone A, Forsberg A, Lindefors N, Halldin C, Lundberg J.

Psychiatry Res. 2016 Jul 30;253:36-42. doi: 10.1016/j.pscychresns.2016.04.016. Epub 2016 Apr 27.

15.

Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.

Sonni I, Fazio P, Schain M, Halldin C, Svenningsson P, Farde L, Varrone A.

J Nucl Med. 2016 Oct;57(10):1529-1534. Epub 2016 May 26.

PMID:
27230923
16.

Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data.

Fazio P, Schain M, Varnäs K, Halldin C, Farde L, Varrone A.

Neuroimage. 2016 Jun;133:313-20. doi: 10.1016/j.neuroimage.2016.03.019. Epub 2016 Mar 17.

PMID:
26994829
17.

In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects.

Kanegawa N, Collste K, Forsberg A, Schain M, Arakawa R, Jucaite A, Lekander M, Olgart Höglund C, Kosek E, Lampa J, Halldin C, Farde L, Varrone A, Cervenka S.

Brain Behav Immun. 2016 May;54:149-57. doi: 10.1016/j.bbi.2016.01.019. Epub 2016 Jan 25.

PMID:
26820224
18.

Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls.

Buchert R, Kluge A, Tossici-Bolt L, Dickson J, Bronzel M, Lange C, Asenbaum S, Booij J, Atay Kapucu LÖ, Svarer C, Koulibaly PM, Nobili F, Pagani M, Sabri O, Sera T, Tatsch K, Vander Borght T, Van Laere K, Varrone A, Iida H.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1323-36. doi: 10.1007/s00259-016-3309-5. Epub 2016 Jan 27.

PMID:
26816194
19.

Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes.

Albert NL, Unterrainer M, Diemling M, Xiong G, Bartenstein P, Koch W, Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, Kapucu LÖ, Kluge A, Ziebell M, Darcourt J, Nobili F, Pagani M, Sabri O, Hesse S, Borght TV, Van Laere K, Tatsch K, la Fougère C.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1315-22. doi: 10.1007/s00259-015-3304-2. Epub 2016 Jan 18.

PMID:
26780619
20.

In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl.

Nag S, Fazio P, Lehmann L, Kettschau G, Heinrich T, Thiele A, Svedberg M, Amini N, Leesch S, Catafau AM, Hannestad J, Varrone A, Halldin C.

J Nucl Med. 2016 Feb;57(2):315-20. doi: 10.2967/jnumed.115.161083. Epub 2015 Nov 19.

Supplemental Content

Loading ...
Support Center